Halozyme Therapeutics, Inc. filed a current report on September 16, 2026, disclosing a proposed offering of $1.05 billion aggregate principal amount of convertible senior notes due 2033.
Key Highlights
- Offering size: Halozyme Therapeutics proposes to offer $1.05 billion aggregate principal amount of convertible senior notes due 2033.
- Overallotment option: The company expects to grant initial purchasers a 13-day option to buy up to an additional $150 million aggregate principal amount of the convertible notes.
- Market conditions: The offering is described as subject to market conditions and other factors, according to the filing.
- Signing authority: The report was signed by Darren Snellgrove, Executive Vice President and Chief Financial Officer.
- Exchange listing: Halozyme Common Stock ($0.001 par value) trades under the symbol HALO on NASDAQ:HALO.
Halozyme Therapeutics Announces Proposed Convertible Senior Notes Offering
Halozyme Therapeutics, Inc., a biopharmaceutical company incorporated in Delaware and headquartered at 12390 El Camino Real, San Diego, California, disclosed on September 16, 2026, that it proposes to offer $1.05 billion aggregate principal amount of convertible senior notes due 2033. According to the filing, the offering is subject to market conditions and other factors, and the company issued a press release on the same date announcing the proposal.
The filing further disclosed that Halozyme expects to grant the initial purchasers of the convertible notes a 13-day option to purchase up to an additional $150 million aggregate principal amount of the same notes. If that option were exercised in full, the total potential offering size would reach $1.2 billion aggregate principal amount, as implied by the figures provided in the filing. The press release announcing the offering is attached as Exhibit 99.1 and incorporated by reference into the filing.
The current report was signed by Darren Snellgrove, Executive Vice President and Chief Financial Officer of Halozyme Therapeutics, Inc. The company holds Commission File Number 001-32335 and its common stock, with a par value of $0.001 per share, is registered on The Nasdaq Stock Market LLC under the trading symbol HALO.
What Was Disclosed
Halozyme Therapeutics disclosed a proposed $1.05 billion convertible senior notes offering due 2033, along with a potential 13-day overallotment option for an additional $150 million, in a current report filed September 16, 2026.



Please wait processing your request...